All In Biotech

Drug Trial Radar · NCT05445908

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

A Phase 2 Clinical Study of SKB264 With/Without KL-A167 in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HER2-negative Breast Cancer Who Have Not Received Prior Systemic Therapy

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 184 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

184

Actual

Start

Aug 17, 2022

Primary completion

Jul 31, 2026

Study completion Jul 31, 2026

Sponsor

Sponsor type
Industry
First posted
Jul 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and tolerability and preliminary antitumor activity of SKB264 with/without KL-A167 in patients with unresectable locally advanced, recurrent or metastatic TNBC and HR+/HER2- BC .The study is divided into three parts.Part 1(TNBC): exploratory phase of the efficacy and safety of the combination treatment. Part 2(TNBC): The subjects will be randomized to treatment group for SKB264 + KL-A167 or SKB264 . Part 3(HR+/HER2- BC): The subjects will be randomized to treatment group for SKB264 + KL-A167 or SKB264 .

Conditions

  • Triple-negative Breast Cancer and HR+/HER2- BC

Interventions

  • SKB264Drug

    SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle

  • KL-A167Drug

    KL-A167 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AEs)Time frame: From baseline up to 30 days after last dose or to the beginning of the new anti-cancer therapy, up to 24 months
  2. Objective Response Rate (ORR)Time frame: From baseline to first documented objective response, up to 24 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.